TG Therapeutics announces $100M share buyback program

[Stock Buybacks theme with US shipping port]
Melpomenem

* TG Therapeutics (NASDAQ:TGTX [https://seekingalpha.com/symbol/TGTX]) announced on Wednesday that its board authorized a new share repurchase program to buy back shares worth up to $100M from time to time through open-market purchases and other transactions.
* The program highlights its resolve to generate value for its shareholders and indicates management’s view that TGTX stock doesn’t adequately reflect the “multibillion-dollar potential” of its lead asset, Briumvi, or the company’s long-term prospects, the biotech said.
* The announcement coincided with the completion of TG’s (NASDAQ:TGTX [https://seekingalpha.com/symbol/TGTX]) previously authorized $100M share buyback program, under which the company has repurchased nearly 3.5M shares at $28.55 per share on average since its launch in August 2024.
* CEO Michael Weiss added that during the month of August alone, the company could buy back roughly $78M worth of TGTX shares at attractive prices. [https://seekingalpha.com/pr/20218944-tg-therapeutics-announces-completion-of-existing-share-repurchase-program-and-authorization]

MORE ON TG THERAPEUTICS

* TG Therapeutics: Looking For The Stimulus For A Turnaround [https://seekingalpha.com/article/4814885-tg-therapeutics-looking-for-stimulus-for-turnaround]
* TG Therapeutics, Inc. (TGTX) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4808350-tg-therapeutics-inc-tgtx-q2-2025-earnings-call-transcript]
* The Play On TG Therapeutics [https://seekingalpha.com/article/4806033-play-on-tg-therapeutics]
* TG Therapeutics falls after Q2 miss despite guidance raise [https://seekingalpha.com/news/4477394-tg-therapeutics-stock-falls-after-q2-miss]
* TG Therapeutics raises BRIUMVI 2025 revenue guidance to $575M while advancing subcutaneous pipeline [https://seekingalpha.com/news/4477313-tg-therapeutics-raises-briumvi-2025-revenue-guidance-to-575m-while-advancing-subcutaneous]